Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
First Claim
1. A stable nanoparticulate heterocyclic amide derivative composition comprising:
- (a) zafirlukast particles having an effective average particle size of less than about 2,000 nm; and
(b) at least one surface stabilizer.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as “active ingredient,” having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma. The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system.
-
Citations
83 Claims
-
1. A stable nanoparticulate heterocyclic amide derivative composition comprising:
-
(a) zafirlukast particles having an effective average particle size of less than about 2,000 nm; and (b) at least one surface stabilizer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. An asthma treatment comprising the following components:
-
(a) about 50 to about 500 g/kg zafirlukast; (b) about 10 to about 70 g/kg hypromellose; (c) about 1 to about 10 g/kg docusate sodium; (d) about 100 to about 500 g/kg sucrose; (e) about 1 to about 40 g/kg sodium lauryl sulfate; (f) about 50 to about 400 g/kg lactose monohydrate; (g) about 50 to about 300 g/kg silicified microcrystalline cellulose; (h) about 20 to about 300 g/kg crospovidone; and (i) about 0.5 to about 5 g/kg magnesium stearate. - View Dependent Claims (16)
-
-
17. An asthma treatment composition comprising the following components:
-
(a) about 100 to about 300 g/kg zafirlukast; (b) about 30 to about 50 g/kg hypromellose; (c) about 0.5 to about 10 g/kg docusate sodium; (d) about 100 to about 300 g/kg sucrose; (e) about 1 to about 30 g/kg sodium lauryl sulfate; (f) about 100 to about 300 g/kg lactose monohydrate; (g) about 50 to about 200 g/kg silicified microcrystalline cellulose; (h) about 50 to about 200 g/kg crospovidone; and (i) about 0.5 to about 5 g/kg magnesium stearate. - View Dependent Claims (18)
-
-
19. An asthma treatment composition comprising the following components:
-
(a) about 200 to about 225 g/kg zafirlukast; (b) about 42 to about 46 g/kg hypromellose; (c) about 2 to about 6 g/kg docusate sodium; (d) about 200 to about 225 g/kg sucrose; (e) about 12 to about 18 g/kg sodium lauryl sulfate; (f) about 200 to about 205 g/kg lactose monohydrate; (g) about 130 to about 135 g/kg silicified microcrystalline cellulose; (h) about 112 to about 118 g/kg crospovidone; and (i) about 0.5 to about 3 g/kg magnesium stearate. - View Dependent Claims (20)
-
-
21. An asthma treatment composition comprising the following components:
-
(a) about 119 to about 224 g/kg zafirlukast; (b) about 42 to about 46 g/kg hypromellose; (c) about 2 to about 6 g/kg docusate sodium; (d) about 119 to about 224 g/kg sucrose; (e) about 12 to about 18 g/kg sodium lauryl sulfate; (f) about 119 to about 224 g/kg lactose monohydrate; (g) about 129 to about 134 g/kg silicified microcrystalline cellulose; (h) about 112 to about 118 g/kg crospovidone; and (i) about 0.5 to about 3 g/kg magnesium stearate. - View Dependent Claims (22)
-
-
23. A stable nanoparticulate zafirlukast composition comprising:
-
(a) particles of a zafirlukast active or a salt thereof; and (b) associated with the surface thereof dioctyl sodium sulfosuccinate and hypromellose; wherein the zafirlukast particles have an effective average particle size of less than about 2,000 nm. - View Dependent Claims (24)
-
- 25. A method of making a nanoparticulate zafirlukast composition comprising contacting zafirlukast particles with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate zafirlukast composition having an effective average particle size of less than about 2,000 nm.
- 44. A method for the treatment of asthma with a nanoparticulate zafirlukast comprising administering to the subject an effective amount of a nanoparticulate composition comprising particles of a zafirlukast having at least one surface stabilizer associated with the surface thereof, wherein the zafirlukast particles have an effective average particle size of less than about 2,000 nm.
-
63. A controlled release composition consisting essentially of:
- (A) a first component comprising a first population of heterocyclic amide derivative nanoparticles; and
(B) at least one subsequent component or formulation comprising a subsequent population of heterocyclic amide derivative nanoparticles and a modified release constituent comprising a modified release coating, a modified release matrix material or mixtures thereof;
wherein the composition, following oral delivery to a subject, delivers the heterocyclic amide derivative nanoparticles in the first and subsequent populations in a pulsatile manner. - View Dependent Claims (64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
- (A) a first component comprising a first population of heterocyclic amide derivative nanoparticles; and
Specification